# EDGAR Filing Document

**Accession Number:** 0001318641
**File Stem:** 0001354457-23-000149
**Filing Date:** 2023-3
**Character Count:** 6632
**Document Hash:** 2a44ef618cf52ecc6ad4883e61368226
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001354457-23-000149.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001354457-23-000149

**CONFORMED SUBMISSION TYPE**: 25-NSE

**CONFIRMING COPY**: 

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Statera Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001318641
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 200077155
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25-NSE
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32954

**BUSINESS ADDRESS:**
- **STREET 1:** 2537 RESEARCH BOULEVARD, SUITE 201
- **CITY:** FORT COLLINS
- **STATE:** CO
- **ZIP:** 80526
- **BUSINESS PHONE:** (888) 613-8802

**MAIL ADDRESS:**
- **STREET 1:** 2537 RESEARCH BOULEVARD, SUITE 201
- **CITY:** FORT COLLINS
- **STATE:** CO
- **ZIP:** 80526

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cytocom, Inc.
- **DATE OF NAME CHANGE:** 20210728

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CLEVELAND BIOLABS INC
- **DATE OF NAME CHANGE:** 20050222
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasdaq Stock Market LLC
- **CENTRAL INDEX KEY:** 0001354457
- **IRS NUMBER:** 521165937
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25-NSE

**BUSINESS ADDRESS:**
- **STREET 1:** One Liberty Plaza
- **CITY:** New York
- **STATE:** NY
- **ZIP:** 10006
- **BUSINESS PHONE:** 301-978-4144

**MAIL ADDRESS:**
- **STREET 1:** Office of General Counsel
- **STREET 2:** 805 King Farm Blvd.
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** The Nasdaq Stock Market LLC
- **DATE OF NAME CHANGE:** 20060224

## Exhibit 99.25

```

Delisting Determination, The Nasdaq Stock Market, LLC,
March 3, 2023, Statera Biopharma, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the common stock of Statera Biopharma, Inc. (the
Company), effective at the opening of the trading session on
March 13, 2023.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rule 5250(c)(1). The Company was notified
of the Staff determination on September 1, 2022. On September 8, 2022,
the Company exercised its right to appeal the Staff determination to
the Listing Qualifications Hearings Panel (Panel) pursuant to Rule 5815.
On September 20, 2022, Staff issued an additional delist determination
for the Company failure to meet the requirement in Listing Rule 5550(a)(2).
A Panel hearing was held on October 6, 2022. On October 11, 2022, Staff
issued an additional delist determination letter for the Company failure
to meet the requirements of Listing Rules 5550(b)(1) and 5250(e)(2)(D).
On October 26, 2022, upon review of the information provided by the Company,
the Panel determined to grant the Company request to remain listed in
the Exchange subject to a series of milestones. After failing to meeting
the Hearings Panel exception, on January 10, 2023, the Hearings Panel
issued a final decision denying the Company continued listing and notified
the Company that trading in the Company securities would be suspended on
January 12, 2023. On January 25, 2023, the Company exercised its right to
appeal the Panel decision and requested a hearing to the Nasdaq Listing and
Hearing Review Council (Council) pursuant to Rule 5820(a).
On February 9, 2023, in application of Rule 5820(a) the Panel issued a letter
deeming the matter closed as the Company had failed to evidence payment of
the appeal fee.  The Staff determination to delist the Company became final
on February 13, 2023.

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 25

### NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

**Commission File Number:** 001-32954

|  |  |
|:---|:---|
| Issuer:                                                                                                             | Statera Biopharma, Inc.                  |
| Exchange:                                                                                                           | Nasdaq Stock Market LLC                  |
| (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |  |
| Address:                                                                                                            | 73 High Street, Buffalo, NEW YORK, 14203 |
| Telephone number:                                                                                                   | 716-849-6810                             |
| (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)   |  |
| (Description of class of securities)                                                                                | Common Stock                             |

---

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- [ ] 17 CFR 240.12d2-2(a)(1)
- [ ] 17 CFR 240.12d2-2(a)(2)
- [ ] 17 CFR 240.12d2-2(a)(3)
- [ ] 17 CFR 240.12d2-2(a)(4)
- [x] Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
- [ ] Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, Nasdaq Stock Market
LLC certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing the Form 25 and has caused this notification to be signed on its
behalf by the undersigned duly authorized person.

| Date       | By   | Name          | Title            |
|:---|:---|:---|:---|
| 2023-03-03 |  | Aravind Menon | Hearings Advisor |

Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR
240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.